Literature DB >> 16341574

Smad3 specific inhibitor, naringenin, decreases the expression of extracellular matrix induced by TGF-beta1 in cultured rat hepatic stellate cells.

Xingjun Liu1, Wei Wang, Han Hu, Ning Tang, Chunling Zhang, Wei Liang, Minwei Wang.   

Abstract

PURPOSE: During the process of liver fibrogenesis, transforming growth factor-beta (TGF-beta) plays an essential role in modulating extracellular matrix (ECM) gene expression, and a growing body of evidence suggests that this is a Smad3-dependent process in the activated hepatic stellate cells (HSCs). Naringenin showed a significantly protective effect on experimental rat liver fibrosis, in our efforts to elucidate its antifibrosis molecular mechanisms and to find a novel target based on Smad3 signaling for challenging fibrosis diseases.
METHODS: In this study, reverse transcription-polymerase chain reaction and Western blot assays were used to investigate the inhibitory effect of naringenin on ECM formation induced by TGF-beta1 in the HSC-T6 cells.
RESULTS: Naringenin reduced not only the accumulation of ECM, including collagen Ialpha1 (Col Ialpha1), fibronectin (FN), and plasminogen activator inhibitor-1 (PAI-1), but also the production of Smad3 induced by TGF-beta1 in both mRNA and protein levels in a dose-dependent manner. Moreover, naringenin selectively inhibited the transcription of Smad3, but not other Smads involved in TGF-beta1 signaling pathways.
CONCLUSION: Our data demonstrate that naringenin can exert antifibrogenic effects by directly or indirectly down-regulating Smad3 protein expression and phosphorylation through TGF-beta signaling.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16341574     DOI: 10.1007/s11095-005-9043-5

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  33 in total

1.  A soluble transforming growth factor beta receptor expressed in muscle prevents liver fibrogenesis and dysfunction in rats.

Authors:  H Ueno; T Sakamoto; T Nakamura; Z Qi; N Astuchi; A Takeshita; K Shimizu; H Ohashi
Journal:  Hum Gene Ther       Date:  2000-01-01       Impact factor: 5.695

Review 2.  Mechanisms of TGF-beta signaling from cell membrane to the nucleus.

Authors:  Yigong Shi; Joan Massagué
Journal:  Cell       Date:  2003-06-13       Impact factor: 41.582

Review 3.  Cellular sources of noncollagenous matrix proteins: role of fat-storing cells in fibrogenesis.

Authors:  A M Gressner; M G Bachem
Journal:  Semin Liver Dis       Date:  1990-02       Impact factor: 6.115

4.  Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene.

Authors:  S Dennler; S Itoh; D Vivien; P ten Dijke; S Huet; J M Gauthier
Journal:  EMBO J       Date:  1998-06-01       Impact factor: 11.598

Review 5.  Fibrogenesis. V. TGF-beta signaling pathways.

Authors:  R G Wells
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2000-11       Impact factor: 4.052

Review 6.  Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis.

Authors:  M J Arthur
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2000-08       Impact factor: 4.052

Review 7.  History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells.

Authors:  A Geerts
Journal:  Semin Liver Dis       Date:  2001-08       Impact factor: 6.115

8.  Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions.

Authors:  N Sanderson; V Factor; P Nagy; J Kopp; P Kondaiah; L Wakefield; A B Roberts; M B Sporn; S S Thorgeirsson
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

9.  PKB/Akt modulates TGF-beta signalling through a direct interaction with Smad3.

Authors:  Ingrid Remy; Annie Montmarquette; Stephen W Michnick
Journal:  Nat Cell Biol       Date:  2004-03-28       Impact factor: 28.824

Review 10.  Controlling the angiogenic switch: a balance between two distinct TGF-b receptor signaling pathways.

Authors:  Marie-Jose Goumans; Franck Lebrin; Gudrun Valdimarsdottir
Journal:  Trends Cardiovasc Med       Date:  2003-10       Impact factor: 6.677

View more
  32 in total

1.  PPARgamma agonists prevent TGFbeta1/Smad3-signaling in human hepatic stellate cells.

Authors:  Caiyan Zhao; Wei Chen; Liu Yang; Lihong Chen; Stephen A Stimpson; Anna Mae Diehl
Journal:  Biochem Biophys Res Commun       Date:  2006-09-22       Impact factor: 3.575

2.  Radiation damage and radioprotectants: new concepts in the era of molecular medicine.

Authors:  M I Koukourakis
Journal:  Br J Radiol       Date:  2012-01-31       Impact factor: 3.039

Review 3.  Cancer prevention and therapy through the modulation of the tumor microenvironment.

Authors:  Stephanie C Casey; Amedeo Amedei; Katia Aquilano; Asfar S Azmi; Fabian Benencia; Dipita Bhakta; Alan E Bilsland; Chandra S Boosani; Sophie Chen; Maria Rosa Ciriolo; Sarah Crawford; Hiromasa Fujii; Alexandros G Georgakilas; Gunjan Guha; Dorota Halicka; William G Helferich; Petr Heneberg; Kanya Honoki; W Nicol Keith; Sid P Kerkar; Sulma I Mohammed; Elena Niccolai; Somaira Nowsheen; H P Vasantha Rupasinghe; Abbas Samadi; Neetu Singh; Wamidh H Talib; Vasundara Venkateswaran; Richard L Whelan; Xujuan Yang; Dean W Felsher
Journal:  Semin Cancer Biol       Date:  2015-04-10       Impact factor: 15.707

Review 4.  A Review on Pharmacological and Analytical Aspects of Naringenin.

Authors:  Kanika Patel; Gireesh Kumar Singh; Dinesh Kumar Patel
Journal:  Chin J Integr Med       Date:  2014-12-10       Impact factor: 1.978

5.  Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.

Authors:  Tzu-Hua Lin; Soo Ok Lee; Yuanjie Niu; Defeng Xu; Liang Liang; Lei Li; Shauh-Der Yeh; Naohiro Fujimoto; Shuyuan Yeh; Chawnshang Chang
Journal:  J Biol Chem       Date:  2013-05-16       Impact factor: 5.157

Review 6.  Hepatoprotective and Anti-fibrotic Agents: It's Time to Take the Next Step.

Authors:  Ralf Weiskirchen
Journal:  Front Pharmacol       Date:  2016-01-07       Impact factor: 5.810

7.  Diosgenin attenuates hepatic stellate cell activation through transforming growth factor-β/Smad signaling pathway.

Authors:  Wei-Lin Xie; Rong Jiang; Xiao-Lu Shen; Zhi-Yu Chen; Xiao-Ming Deng
Journal:  Int J Clin Exp Med       Date:  2015-11-15

8.  Combination of Asiatic Acid and Naringenin Modulates NK Cell Anti-cancer Immunity by Rebalancing Smad3/Smad7 Signaling.

Authors:  Guang-Yu Lian; Qing-Ming Wang; Patrick Ming-Kuen Tang; Shuang Zhou; Xiao-Ru Huang; Hui-Yao Lan
Journal:  Mol Ther       Date:  2018-06-22       Impact factor: 11.454

Review 9.  Modulation of the tumor microenvironment by natural agents: implications for cancer prevention and therapy.

Authors:  Haseeb Zubair; Mohammad Aslam Khan; Shashi Anand; Sanjeev Kumar Srivastava; Seema Singh; Ajay Pratap Singh
Journal:  Semin Cancer Biol       Date:  2020-05-26       Impact factor: 15.707

10.  Smad3-Targeted Therapy Protects against Cisplatin-Induced AKI by Attenuating Programmed Cell Death and Inflammation via a NOX4-Dependent Mechanism.

Authors:  Qin Yang; Li Gao; Xiao-Wei Hu; Jia-Nan Wang; Yao Zhang; Yu-Hang Dong; Hui Yao Lan; Xiao-Ming Meng
Journal:  Kidney Dis (Basel)       Date:  2021-02-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.